| Objective Echinoderm microtubuleassociated protein-like 4-anaplastie lymphoma kinase(EML4-ALK)fusion gene is one of the common drive of non-small cell Lung cancer(NSCLC) patients. To investigate the factors of detection methods ,clinical features, therapies and prognosis of patients who harbor EML4-ALKfusion gene, and to analyze the relationships between the gene status on EML4-ALK fusion gene and EGFR, KRAS, or BRAFmutation.Methods Total 190 cases of formalin-fixed and paraffin-embedded (FFPE) specimens of NSCLC patients were detected by immunohistochemical (IHC) for EML4-ALK fusion gene,and then the IHC-positive specimens were identified by RT-PCR to confirm the gene status.The RT-PCR platform was utilized in this study to detect the status of EGFR, KRAS, and BRAFof all the 190 specimens.Results Among the 190 NSCLC patients, 17 patients who harbor EML4-ALK fusion gene were detected. The surgical specimens was 47.1%(8/17) (x2=25.999,P=0.000) . 76.5% (13/17) patients' age were no more than 60 years (x2=5.813,P=0.016) .There was no patient who harbor EML4-ALK fusion gene and EGFR or KRAS or BRAF mutation in same time in the research.In ?-?a stages,8 cases of EML4-ALK fusion gene positive patients were detected whose 2 years survival was 100% after operating and postoperative chemotherapy. 9 cases of advanced stage patients who experienced low efficiency in chemotherapy of which 5 patients had already dead. Patients who achieved stabledisease or partial response used Crizotinib whose ORR and DCR was 50% and 100% respectively. Patients who suffered disease progress after multi-line therapies used Crizotinib 2 months whose ORR and DCR still can reach 33.3% and66.7%.Conclusion EML4-ALK fusion gene significantly associates with age, whereas gender, smoking history and other clinical features are not. Crizotinib could increase ORR and DCR after multi-line therapies in NSCLC patients harbor EML4-ALK fusion gene. |
PDF Full Text Request